Monitoring EGFR-lung cancer evolution: a possible beginning of a "methylation era" in TKI resistance prediction.

ABSTRACT: The advances in scientific knowledge on biological therapies of the last two decades have impressively oriented the clinical management of non-small-cell lung cancer (NSCLC) patients. The treatment with tyrosine kinase inhibitors (TKIs) in patients harboring Epidermal Growth Factor Receptor (EGFR)-activating mutations is dramatically associated with an improvement in disease control. Anyhow, the prognosis for this selected group of patients remains unfavorable, due to the innate and/or acquired resistance to biological therapies. The methylome analysis of many tumors revealed multiple patterns of methylation at single/multiple cytosine-phosphate-guanine (CpG) sites that are linked to the modulation of several cellular pathways involved in cancer onset and progression. In lung cancer

SUBMITTER: Fabrizio FP 

PROVIDER: S-EPMC10157092 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature